1. Introduction 2. Approved and Clinical Trial Third Generation EGFR inhibitors 3. Current approaches in the development of Covalent Irreversible EGFR Inhibitors 4. Current approaches in the development of Covalent Reversible EGFR Inhibitors 5. Mechanism of Resistance to Third Generation Inhibitors 6. Discovery of Fourth Generation Allosteric C797S Inhibitors 7. Conclusion and Future Perspectives
Harun Patel is an Associate Professor in the Division of Computer Aided Drug Design, at the R. C. Patel Institute of Pharmaceutical Education and Research's Dept. of Pharmaceutical Chemistry. In addition to being the recipient of multiple awards, Dr Patel has over 70 publications in reputed peer reviewed international journals (which have achieved over 600 citations), three international books, and two patents to his name. His key research interests involve QSAR, docking studies, virtual screening, and synthesis of novel anticancer, anti-tubercular and antiepileptic drugs.
Rahul Pawara is an Associate Professor in the Division of Computer Aided Drug Design, at the R. C. Patel Institute of Pharmaceutical Education and Research's Dept. of Pharmaceutical Chemistry, which he joined following two years of work as a Field Officer in an ICMR-funded project studying Tuberculosis in tribal areas. He has five international publications in peer reviewed journals, and his main research interest is the design and synthesis of novel anti-cancer agents.